Skip to main content

Table 1 Clinical characteristics

From: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients

Characteristics

Patients

N (%)

 

Gender

 

 Male

18 (53%)

 Female

16 (47%)

Age (median, range)

60 (29–85)

ECOG PS

 

 0

2 (6%)

 1

17 (50%)

 2

12 (35%)

 3

3 (9%)

Tumour site

 

 Stomach

11 (32.4%)

 Small Intestine

10 (29.4%)

 Mesentery

7 (20.6%)

 Other

6 (17.6%)

 (peritoneum3, colon 1, rectum 1, oesophagus 1)

 

Metastatic sites

 

 Liver

28 (82%)

 Peritoneum

25 (73.5%)

 Lung

4 (12%)

 Other

10 (29.5%)

Transfusion before EPO treatment

 

 Yes

10 (29%)/

 No

24 (71%)

Starting Dose of Imatinib/day

 

 400 mg

25(67.6%)

 800 mg

9(11.7%)